Share on StockTwits
 

DeVry (NYSE:DV) issued its quarterly earnings data on Tuesday. The company reported $0.74 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.73 by $0.01, AmericanBankingNews.com reports. The company had revenue of $491.30 million for the quarter, compared to the consensus estimate of $478.75 million. During the same quarter in the prior year, the company posted $0.87 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis.

A number of analysts have recently weighed in on DV shares. Analysts at Thomson Reuters/Verus upgraded shares of DeVry from a “sell” rating to a “hold” rating in a research note to investors on Monday. On a related note, analysts at Barclays raised their price target on shares of DeVry from $28.00 to $40.00 in a research note to investors on Wednesday, January 29th. They now have an “equal weight” rating on the stock. Finally, analysts at Ned Davis Research upgraded shares of DeVry from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, January 21st. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $33.67.

Shares of DeVry (NYSE:DV) traded up 2.24% on Tuesday, hitting $36.12. 1,033,875 shares of the company’s stock traded hands. DeVry has a 52-week low of $25.33 and a 52-week high of $40.22. The stock has a 50-day moving average of $36.60 and a 200-day moving average of $33.48. The company has a market cap of $2.285 billion and a P/E ratio of 33.55.

DeVry Inc (NYSE:DV) is a provider of educational services and the parent organization of Advanced Academics, American University of the Caribbean School of Medicine, Becker Professional Education, Carrington College and Carrington College California, Chamberlain College of Nursing, DeVry Brasil, DeVry University, Ross University School of Medicine and Ross University School of Veterinary Medicine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.